Cross-Sector entity
funding is the sole category represented across all 2 tracked stories. Of the tracked stories, 2 of 2 also mention Ibogaine, the most common co-covered peer. Psyence Labs Ltd. appears in 2 tracked Cross-Sector stories from February 21, 2026. The tracked stories average 2 original sources each.
2 verified stories tracked
Last mentioned: Feb 21, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
funding is the sole category represented across all 2 tracked stories. Of the tracked stories, 2 of 2 also mention Ibogaine, the most common co-covered peer. Psyence Labs Ltd. appears in 2 tracked Cross-Sector stories from February 21, 2026. The tracked stories average 2 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Psyence Labs Ltd.. Shared-story counts are live from our verified record — not editorial picks.
Valuation Period
Expected timeframe for determining the fair market value of the equity investment.
Option Exercised
PsyLabs officially triggers the put option, requiring an equity investment from PBM.
Strategic Investment Announced
Psyence BioMed announces it will make an equity investment in PsyLabs at fair market value.
Put Option Established
Psyence BioMed and PsyLabs enter into a strategic put option agreement.
Psyence Biomedical Ltd. (Nasdaq: PBM) has announced a strategic equity investment in PsyLabs Ltd. after the manufacturer exercised its rights under a previously established put option agreement. This move strengthens the relationship between the biopharmaceutical developer and its primary supplier of nature-derived psychedelic compounds.
Psyence Biomedical Ltd. (Nasdaq: PBM) has confirmed a strategic equity investment in PsyLabs following the exercise of a previously established put option. This move deepens the integration between the biopharmaceutical developer and its primary manufacturer of pharmaceutical-grade psychedelic compounds.
Source: CBJ (ca) · manilatimes.net
